Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2009
FOR IMMEDIATE RELEASE - September 21, 2009 – San Francisco, CA.
The TCT 2009 meeting will feature an unusual amount of novel information about Vulnerable Coronary Artery Plaque, the structure widely considered to the primary cause of acute coronary events, the leading cause of death in the developed world. The concept of Vulnerable Plaque has been a topic of study for over 2 decades. TCT will showcase progress on a number of diagnostic catheters designed to identify the lipid core plaques that are widely suspected to be vulnerable.
- Monday, September 21 – Four presentations in the day-long Vulnerable Plaque Symposium describing the experience with LipiScan, a novel near-infrared spectroscopy catheter (InfraReDx, Inc.) approved in 2008 by the FDA for identification of lipid core plaques. (Room 131)
- Thursday, September 24 - Dr. Gregg Stone will present the results of the 3 year follow-up of suspected vulnerable plaques in the Prospect Trial, a study of over 700 patients with multi-vessel ultrasound (Virtual Histology, Volcano, Inc.) measurements at baseline. This major trial is the first, large, long-term study of the hypothesis that harmful vulnerable plaques can be identified before they cause a coronary event. (Room 300)
In 1989, Dr. James Muller and colleagues introduced the term “Vulnerable Plaque” to describe a plaque at high risk of disruption that leads to coronary thrombosis. Dr. Muller, CEO of InfraReDx, Inc. participated in the company’s founding in 1998 for the purpose of developing a spectroscopic catheter to detect vulnerable plaque. Dr. Muller will be available at TCT to comment on the important developments related to vulnerable plaque reported at the meeting, including commentary on the outcome of the Prospect Trial. Dr. Muller and his colleague, Jim Dillon, Vice-President of Sales and Marketing at InfraReDx, Inc. will be available for comment on the use of the LipiScan system, the only FDA cleared product to detect lipid core plaque and the InfraReDx experience in over 400 patients. The commercially available LipiScan™ Coronary Imaging System will be displayed in the “Emerging Technologies” section at booth # 2410.
· References
- Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Clinical Progress Series. Circulation 1989; 79:733-743.
- Muller JE, Abela GS, Nesto RW, Tofler GH. Triggers, acute risk factors, and vulnerable plaques: The lexicon of a new frontier. J Am Coll Cardiol 1994;23:809-813.
About InfraReDx, Inc.
InfraReDx, Inc., headquartered in Burlington, Massachusetts, was founded in 1998 and is a privately-funded medical device company developing a fiber-optic, catheter-based, near-infrared (NIR) spectroscopy system to identify and characterize vulnerable plaque in the coronary arteries. For more information, visit www.infraredx.com.
About TCT 2009
Transcatheter Cardiovascular Therapeutics (TCT) is organized by the Cardiovascular Research Foundation, which is dedicated to research and education in the broad subspecialty of interventional cardiology and endovascular medicine. TCT is scheduled from Monday, September 21st to Friday, September 25th, in San Francisco, CA. at the Moscone Center. This scientific meeting is one of the world’s largest events for those performing cardiac diagnostics and interventions. This meeting is the primary annual meeting for the world-wide interventional cardiology community. For more information, visit www.tctconference.com
Company Contacts:
Dr. Muller Contact: Investor Contact: Media Contact:
Carolyn Rogers Jeff Mazur Jim Dillon
InfraReDx, Inc. InfraReDx, Inc. InfraReDx, Inc.
(781) 345-9644 (781) 345-9626 (781) 345-9679
crogers@infraredx.com jmazur@infraredx.com jdillon@infraredx.com
